SciELO - Scientific Electronic Library Online

 
vol.83 número2Excreción de SARS-CoV-2 infeccioso en dos niños asin tomáticosDrogas antiepilépticas y anestésicas en la unidad de terapia intensiva. Su impacto en la mortalidad en el estado de mal epiléptico no convulsivo índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Medicina (Buenos Aires)

versão impressa ISSN 0025-7680versão On-line ISSN 1669-9106

Resumo

SALAZAR, Martín et al. Early use of tocilizumab in hospitalized patients with severe and critical COVID-19 in the Province of Buenos Aires: a multicentric study. Medicina (B. Aires) [online]. 2023, vol.83, n.2, pp.190-201. ISSN 0025-7680.

Introduction: Tocilizumab (TCZ), an IL-6 receptor antagonist monoclonal antibody is warranted in severe and critically-ill COVID-19 patients. The objective was to evaluate 28-day mortality of patients with severe or critical COVID-19 treated with early vs delayed TCZ.

Methods: Multicenter, retrospective cohort study in cluding patients>18 years hospitalized between 7/1/2021- 8/1/2022 with confirmed COVID-19, with 5, 6 and 7 points of WHO Ordinal Initial Severity Scale [SS]. Early or late administration was considered if TCZ was administered before or after 48 hours from admission. Outcomes were28-day mortality and change of SS. Factors related to 28-day mortality were evaluated with Cox regression.

Results: 266 patients were included, 159(60%) male; aged 58(± 15); frequent comorbidities were hypertension (42%), obesity (37%) and diabetes (27%). Seventy patients had a SS = 5 (Supplemental O2), 143 had SS = 6 (NIV/ HFNC), and 53 had SS = 7 (IMV). 28-day mortality was 42%(112/266); predictors were age, obesity, higher SS, days between hospitalization and TCZ administration, and fewer days between symptoms onset and TCZ. Mortality of SS 5, 6 and 7 was 26%, 39% and 72% respectively. Com pared with baseline SS points, 76% and 62% of patients remained stable or improved on days 3 and 7 since TCZ administration. 28-day mortality was lower when TCZ was administered before 48 hours (39% vs 57%; p = 0.02; HR = 0.63;[0.41-0.99, p = 0.05]).

Discussion: This study supports the early use of TCZ in patients with severe or critical COVID-19.

Palavras-chave : Tocilizumab; COVID-19; Anti-interleukin-6 receptor; SARS-CoV-2.

        · resumo em Espanhol     · texto em Espanhol